AGT and diabetes mellitus: Similarly, large trials, such as the “Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL),” “Action to Control Cardiovascular Risk in Diabetes (ACCORD),” “Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT),” and “Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE),” demonstrated that aggressive risk factor control in African Americans using antihypertensive, antihyperglycemic, or lipid-lowering medications is beneficial [29-33].